What is AI Proteins?
Founded in 2021 and headquartered in Andover, MA, AI Proteins is at the forefront of synthetic biology, specializing in the de novo design and creation of novel proteins. This focus positions the company to address complex challenges in drug discovery, materials science, and beyond by engineering proteins with tailored functionalities. The company's commitment to innovation in this specialized field is a key driver for its continued investment.
How much funding has AI Proteins raised?
AI Proteins has raised a total of $59.7M across 2 funding rounds:
Angel/Seed
$18.2M
Series A
$41.5M
Angel/Seed (2022): $18.2M with participation from Lightchain Capital and Cobro Ventures
Series A (2025): $41.5M led by Lightchain Capital, Mission BioCapital, Santé Ventures, and Cobro Ventures
Key Investors in AI Proteins
Lightchain Capital
Lightchain Capital is a venture capital fund that specializes in investing in early-stage life sciences companies. The firm is dedicated to supporting innovations aimed at improving patient outcomes in cancer treatment. Their portfolio includes companies focused on developing advanced therapeutic solutions and strategic collaborations in oncology. Lightchain Capital targets clients within the life sciences sector who are committed to transformative healthcare advancements.
Cobro Ventures
Cobro Ventures is a private investment firm specializing in technology and biotechnology sectors. With a team boasting over 25 years of experience in founding, operating, and investing in tech businesses, they focus on creating significant value during critical innovation phases. The firm supports projects ranging from network performance management to targeted protein degradation and AI-guided therapy. Cobro Ventures aims to make a substantial impact by collaborating with world-class experts and leveraging their expertise in intellectual property and strategic business development.
Mission BioCapital
Mission BioCapital is a venture capital firm that provides early-stage capital to innovative life science entrepreneurs. Founded in 2009, the company focuses on empowering startups through mentorship, collaboration, and a commitment to accelerating the development of scientific solutions. Their approach emphasizes creativity and respect for founders, aiming to revolutionize the journey from discovery to medical breakthroughs. With shared lab spaces and a strong team of scientists and investors, Mission BioCapital supports the next generation of life science companies in making transformational investments.
What's next for AI Proteins?
The recent major strategic investment signals a pivotal phase for AI Proteins, likely enabling the company to scale its research and development efforts, expand its intellectual property portfolio, and potentially move towards clinical validation or commercialization of its synthetic protein platforms. This infusion of capital is expected to accelerate the company's mission to revolutionize protein engineering and its applications across various industries, solidifying its position as a leader in synthetic biology.
See full AI Proteins company page
